Is This the Right Time to Hold EW Stock in Your Portfolio?
Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.
EW - Edwards Lifesciences Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$104.63
DETAILS
HIGH:
$110.00
LOW:
$95.00
MEDIAN:
$105.50
CONSENSUS:
$104.63
UPSIDE:
15.54%
Stock News
FDA Approval of Edwards Lifesciences' PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy who are deemed at intermediate or greater risk for surgery and deemed appropriate for transcatheter edge-to-edge tr.
Is EW Overvalued? DCF Says Worth $40
On October 21, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown a 17.3% increase in price over the past year bu
Edwards Lifesciences Corporation $EW Stock: Birch Hill Investment Advisors LLC Trims Position
Birch Hill Investment Advisors LLC lowered its stake in Edwards Lifesciences Corporation (NYSE: EW) by 1.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 723,022 shares of the medical research company's stock after selling 12,355 shares during the quarter. Edwards Lifesciences
First Citizens Bank & Trust Co. Makes New $792,000 Investment in Edwards Lifesciences Corporation $EW
First Citizens Bank and Trust Co. bought a new stake in Edwards Lifesciences Corporation (NYSE: EW) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,174 shares of the medical research company's stock, valued at approximately $792,000. Other
Edwards Lifesciences Corporation $EW Stock: Assenagon Asset Management S.A. Boosts Stake
Assenagon Asset Management S.A. grew its holdings in shares of Edwards Lifesciences Corporation (NYSE: EW) by 50.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,719,271 shares of the medical research company's stock after buying an additional 906,345 shares during the
Analyzing Elutia (NASDAQ:ELUT) and Edwards Lifesciences (NYSE:EW)
Elutia (NASDAQ: ELUT - Get Free Report) and Edwards Lifesciences (NYSE: EW - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings. Analyst Ratings This is a summary of current recommendations
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifescie.
Edwards Lifesciences to Host Investor Event in Conjunction With TCT
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team. A live webcast of the event will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived versio.
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement. For many pediatric patients, pulmonary valve replacement is not a one-time event. The AUTUS valve is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy,.
Is EW Overvalued? DCF Says Worth $40
On September 30, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown a mixed price performance recently, with a ye
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
Edwards Lifesciences NYSE: EW outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE, SAPIEN M3 and surgical therapies.
Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
EW DCF Analysis: Intrinsic Value $53 vs Price $86
On September 16, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has experienced a mixed price performance recently. The
Edwards Lifesciences Comments on TAVR National Coverage Decision
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team. Aortic stenosis is a serious, pro.
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl.
128,603 Shares in Edwards Lifesciences Corporation $EW Acquired by Beacon Pointe Advisors LLC
Beacon Pointe Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 128,603 shares of the medical research company's stock, valued at approximately $11,632,000. A number of
Is EW Overvalued? DCF Says Worth $53
On August 26, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has seen a price performance of +12.4% over the past year
Bank of Nova Scotia Takes Position in Edwards Lifesciences Corporation $EW
Bank of Nova Scotia bought a new position in Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 60,417 shares of the medical research company's stock, valued at approximately $5,465,000. Several other hedge funds also recently made
Price Targets
Edwards Lifesciences upgraded to Buy from Neutral at UBS
$110.00
(was $83.04)
UBS
Edwards Lifesciences price target raised to $101 from $100 at Piper Sandler
$101.00
(was $83.82)
Piper Sandler
Edwards Lifesciences upgraded to Outperform from Market Perform at Leerink
$101.00
(was $83.82)
Mike Kratky
·
Leerink Partners
Edwards Lifesciences price target raised to $95 from $90 at Truist
$95.00
(was $86.78)
Richard Newitter
·
Truist Financial
Edwards Lifesciences price target raised to $110 from $100 at RBC Capital
$110.00
(was $92.03)
RBC Capital
Edwards Lifesciences price target raised to $100 from $93 at Evercore ISI
$100.00
(was $93.11)
Evercore ISI
Edwards Lifesciences price target raised to $110 from $100 at BTIG
$110.00
(was $91.18)
Marie Thibault
·
BTIG
Edwards Lifesciences price target raised to $110 from $104 at Barclays
$110.00
(was $84.15)
Barclays
Edwards Lifesciences price target raised to $90 from $89 at Truist
$90.00
(was $83.15)
Truist Financial
Edwards Lifesciences price target raised to $93 from $92 at Evercore ISI
$93.00
(was $83.12)
Vijay Kumar
·
Evercore ISI
Edwards Lifesciences price target raised to $100 from $98 at BTIG
$100.00
(was $79.72)
BTIG
Edwards Lifesciences price target lowered to $85 from $87 at Canaccord
$85.00
(was $79.72)
William Plovanic
·
Canaccord Genuity
Edwards Lifesciences price target lowered to $95 from $100 at Mizuho
$95.00
(was $77.28)
Mizuho Securities
Edwards Lifesciences price target lowered to $89 from $92 at Truist
$89.00
(was $76.85)
Richard Newitter
·
Truist Financial
Edwards Lifesciences price target lowered to $95 from $108 at Goldman Sachs
$95.00
(was $77.05)
David Roman
·
Goldman Sachs
Edwards Lifesciences price target raised to $100 from $98 at Piper Sandler
$100.00
(was $77.05)
Piper Sandler
Edwards Lifesciences price target lowered to $94 from $95 at UBS
$94.00
(was $81.62)
Danielle Antalffy
·
UBS
Edwards Lifesciences price target raised to $110 from $105 at Stifel
$110.00
(was $84.35)
Stifel Nicolaus
Edwards Lifesciences price target raised to $98 from $95 at Piper Sandler
$98.00
(was $84.35)
Piper Sandler
Edwards Lifesciences price target raised to $95 from $92 at UBS
$95.00
(was $83.58)
Danielle Antalffy
·
UBS